Phase 2 N=50 Trial of Curcumin in Advanced Pancreatic Cancer
Pancreatic Neoplasms · Adenocarcinoma
Primary: Six-Month Participant Survival — 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=19 Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis
Oral Mucositis · Oral Cancer
Primary: Oral Mucositis Severity - WHO Scale — 3; 3; 0; 0 participants
Phase 3 N=25 A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa
Hemophilia A With Inhibitors · Hemophilia B With Inhibitors
Primary: Proportion of Successfully Treated Mild/Moderate Bleeding Episodes Per FDA Requirement. — 0.654; 0.603 Proportion of successfully treated BEs
Phase 2 N=30 Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration
Wet Age-related Macular Degeneration
Primary: Best Corrected Visual Acuity (BCVA) — 7.0 letters
N/A N=108 Development and Preliminary Trial of a Brief, Portable Health Intervention for Rural Sexual Minority Emerging Adults
Depression · Suicidality · Substance Abuse
Primary: Change in Depression. — 24.75; 25.17; 29.06; 21.03 units on a scale — p=<0.01
Phase 4 N=84 Does Rosuvastatin Delay Progression of Atherosclerosis in HIV
HIV · Cardiovascular Disease
Primary: Progression of Carotid Intima Media Thickness — 0.0062; 0.004 mm — p=0.684
Phase 2 N=26 Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration
Wet Age-related Macular Degeneration
Primary: Best Corrected Visual Acuity (BCVA) — 2.0 letters
Phase 3 N=205 Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
Alzheimer Disease
Primary: Risk Ratio for AD Symptom Progression on CDR-SB — 119; 43; 10; 5 Participants — p=0.0313
N/A N=304 Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD
Major Depressive Disorder
Primary: Mean Change From Baseline in SIGH-D-17 Score at 8 Weeks. — -9.70; -10.16 units on a scale
Phase 4 N=60 Dexmedetomidine Versus Morphine and Midazolam in Prevention and Treatment of Delirium After Adult Cardiac Surgery
Delirium
Primary: The Incidence of Delirium (Number of Patients (in Digits)) — 1; 2 participants
Phase 2 N=97 Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin
Vaginitis Gardnerella
Primary: The Proportion of Participants With Eradication of Gardnerella Vaginalis (GV) in Each Study Arm at Visit 2 (Day 15-21) as Assessed by Nucleic Acid Amplification Test…
N/A N=40 Refitting Somofilcon A Toric Contact Lens Wearers Into Fanfilcon A Toric Lenses for 4-weeks of Wear
Astigmatism
Primary: Lens Centration - Somofilcon A Toric (Habitual) Lens — 100; 0; 0 percentage of lenses
N/A N=56 Evaluation of Natureheme-iron on Iron Absorption Effect and Anti-oxidation Functions
Anemia
Primary: The Hemoglobin of the Subjects at Baseline and 6 Weeks — 0.38; 0.29; 0.57 g/dl
Phase 3 N=44 An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
Psoriasis
Primary: Percentage of Participants With Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12 — 77.3 percentage of participants
Phase 1 N=29 Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
Progressive Supranuclear Palsy · Corticobasal Degeneration
Primary: Flortaucipir Imaging in PSP, CBD and Healthy Volunteers — 1.17; 1.12; 1.03; 1.15 standardized uptake value ratio (SUVr)